Alterity Therapeutics Adds Biotech Veteran Ann Cunningham to Guide Phase 3 MSA Trial
Alterity Therapeutics has appointed Ann Cunningham, an executive with over 25 years at Eli Lilly and Teva Pharmaceuticals, to its board as an independent non-executive director effective April 17. Her commercial leadership will support advancement of the ATH434 asset into a pivotal Phase 3 trial in Multiple System Atrophy.
1. Board Appointment and Role
On April 17, Alterity Therapeutics appointed Ann Cunningham as an independent non-executive director to strengthen its board composition. This strategic move is timed to bolster commercial and strategic expertise as the company transitions ATH434 into a late-stage development program.
2. Cunningham’s Pharmaceutical and Biotech Background
Cunningham brings over 25 years of global experience, having led marketing and sales teams at Eli Lilly and Company and Teva Pharmaceuticals. Her track record includes launching Cymbalta® and Rexulti®, and she founded i³ Strategy Partners to advance patient engagement in underserved communities.
3. Advancing ATH434 Phase 3 for MSA
Alterity is preparing to initiate a pivotal Phase 3 trial of ATH434 in Multiple System Atrophy following positive Phase 2 results. Cunningham’s expertise is expected to shape commercial strategy, maximize pipeline value and support future market entry for the first disease-modifying MSA therapy.